七氟烷对心脏手术体外循环炎症反应影响:随机对照试验研究方案
主要终点为体外循环期间血清PMN-弹性蛋白酶水平以评估炎症反应,次要终点包括其他促炎和抗炎细胞因子、外周血microRNA表达及临床结局。该试验旨在确定体外循环期间加用挥发性麻醉药是否减轻炎症反应。
要点
- 主要终点为体外循环期间血清PMN-弹性蛋白酶水平,评估炎症反应。
- 次要终点包括细胞因子、microRNA表达及术后主要并发症和住院时间。
核心结论
- 该试验可能确定体外循环期间加用挥发性麻醉药是否减轻炎症反应。
关键数值与推荐
- 主要终点为体外循环期间血清PMN-弹性蛋白酶水平。
- 次要终点包括血清IL-1β、IL-6、IL-8、TNFα、TGFβ、IL-10水平及外周血microRNA表达。
- 临床终点包括术后主要并发症发生率及住院和重症监护室停留时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent experimental evidence shows that sevoflurane can reduce the inflammatory response during cardiac surgery with cardiopulmonary bypass. However, this observation so far has not been assessed in an adequately powered randomized controlled trial. METHODS: We plan to include one hundred patients undergoing elective coronary artery bypass graft with cardiopulmonary bypass who will be randomized to receive either volatile anesthetics during cardiopulmonary bypass or total intravenous anesthesia. The primary endpoint of the study is to assess the inflammatory response during cardiopulmonary bypass by measuring PMN-elastase serum levels. Secondary endpoints include serum levels of other pro-inflammatory markers (IL-1β, IL-6, IL-8, TNFα), anti-inflammatory cytokines (TGFβ and IL-10), and microRNA expression in peripheral blood to achieve possible epigenetic mechanisms in this process. In addition clinical endpoints such as presence of major complications in the postoperative period and length of hospital and intensive care unit stay will be assessed. DISCUSSION: The trial may determine whether adding volatile anesthetic during cardiopulmonary bypass will attenuate the inflammatory response. TRIAL REGISTRATION: ClinicalTrials.gov NCT02672345 . Registered on February 2016 and updated on June 2020.
引用
- Cardoso TAAM, Kunst G, Neto CN, et al. Effect of sevoflurane on the inflammatory response during cardiopulmonary bypass in cardiac surgery: the study protocol for a randomized controlled trial. Trials. 2021. PMID: 33407763. doi:10.1186/s13063-020-04809-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。